Collen Masimirembwa

Last updated

Collen Masimirembwa
Born1967 (age 56–57)
NationalityZimbabwean
CitizenshipZimbabwe
Occupation(s)President and chief scientific officer of the African Institute of Biomedical Science and Technology
Known for Pharmacogenetics, pharmacology, and drug discovery
AwardsFellow of the African Academy of Sciences, Fellow of the Zimbabwe Academy of Sciences, HUGO Africa Award

Collen Masimirembwa is a biomedical pharmacologist from Zimbabwe. He is a Distinguished Professor of Clinical Pharmacology at the University of Witswatersrand, [1] and serves as the President and Chief Scientific Officer at the African Institute of Biomedical Science and Technology (AiBST). His research in Africa has contributed to the field of pharmacogenetics, particularly in understanding the genetic diversity and drug response of African populations. In 2018, he was awarded the HUGO Africa Award. [2] He is a fellow of the Calestous Juma Leadership Fellowship, [3] African Academy of Sciences (AAS) and the Zimbabwe Academy of Sciences (ZAS).

Contents

He has authored over 100 papers in peer-reviewed journals and book chapters and has guided numerous postgraduate students and postdoctoral fellows. [4]

Early life and education

Masimirembwa was born in 1967 in Zimbabwe [5] and received his BSc (Hons) and DPhil degrees in Biochemistry from the University of Zimbabwe in 1993. [6] Fascinated by the then-emerging field of pharmacogenetics, he conducted studies at the Karolinska Institute in Sweden in 1995 [5] , where he earned his PhD in Medical Biochemistry and Biophysics. His doctoral research was centered on the molecular mechanisms of drug metabolism and toxicity. [7] [8]

Career and research

After obtaining his PhD, Masimirembwa returned to the University of Zimbabwe and served as a Senior Lecturer and Head of the Department of Biochemistry from 1992 to 1997. [6] He later joined AstraZeneca R&D in Sweden as a Principal Scientist and Project Leader, focusing on drug discovery and development in various areas such as cardiovascular, gastrointestinal, and infectious diseases. He played a key role in establishing the AstraZeneca Africa Pharmacogenetics Research Network, which aimed to study the genetic diversity and drug response of African populations. [7] [6]

Later in 2008, Masimirembwa founded and assumed the position of President and Chief Scientific Officer at the African Institute of Biomedical Science and Technology (AiBST), a non-profit research institute in Zimbabwe that focuses on biomedical science and technology, with an emphasis on pharmacogenetics and clinical pharmacology. [9]

At the institute, he manages collaborations with various academic, industry, and government partners. He also leads the African Pharmacogenomics Consortium (APC), a network that aims to advance pharmacogenomics research and applications in Africa. [6] He is also a Distinguished Professor of Health Sciences Research at the University of the Witwatersrand (South Africa). [7] [10]

Masimirembwa is a fellow of the Zimbabwe Academy of Sciences (ZAS) [5] and the African Academy of Sciences (AAS) among many other honors. In November 2021, Masimirembwa was selected as a Calestous Juma Science Leadership Fellow by the Bill and Melinda Gates Foundation, to develop a research and innovation ecosystem, train scientists, and create centres of excellence in genomic medicine research to enhance Africa’s sustainable development in genomic and pharmaceutical capabilities. [11]

Selected publications

Awards

Collen Masimirembwa was named a Fellow of the Zimbabwe Academy of Sciences in 2017 and the African Academy of Sciences in 2018. In 2018, he was awarded the HUGO Africa Award. [12] The Grand Challenges Africa Award was presented to him in 2016. He was the recipient of the EDCTP Senior Fellowship Award in 2014 [13] and the Wellcome Trust Senior Fellowship Award in 2012. AstraZeneca R&D acknowledged his work with the Global Scientific Award in 2006 and the Global Innovation Award in 2005. [7] [11] Additionally, he received the Calestous Juma Leadership Fellowship in 2021 [14] and the PMCW 2025 Pioneer Award. [15]

Related Research Articles

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Omeprazole</span> Medication to treat gastroesophageal reflux disease and other conditions

Omeprazole, sold under the brand names Prilosec and Losec, among others, is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to that of other PPIs. It can be taken by mouth or by injection into a vein. It is also available in the fixed-dose combination medication omeprazole/sodium bicarbonate as Zegerid and as Konvomep.

<span class="mw-page-title-main">Pharmacogenomics</span> Study of the role of the genome in drug response

Pharmacogenomics, often abbreviated "PGx," is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of a patient affects their response to drugs. It deals with the influence of acquired and inherited genetic variation on drug response, by correlating DNA mutations with pharmacokinetic, pharmacodynamic, and/or immunogenic endpoints.

<span class="mw-page-title-main">CYP2D6</span> Human liver enzyme

Cytochrome P450 2D6 (CYP2D6) is an enzyme that in humans is encoded by the CYP2D6 gene. CYP2D6 is primarily expressed in the liver. It is also highly expressed in areas of the central nervous system, including the substantia nigra.

<span class="mw-page-title-main">CYP2C19</span> Mammalian protein found in humans

Cytochrome P450 2C19 is an enzyme protein. It is a member of the CYP2C subfamily of the cytochrome P450 mixed-function oxidase system. This subfamily includes enzymes that catalyze metabolism of xenobiotics, including some proton pump inhibitors and antiepileptic drugs. In humans, it is the CYP2C19 gene that encodes the CYP2C19 protein. CYP2C19 is a liver enzyme that acts on at least 10% of drugs in current clinical use, most notably the antiplatelet treatment clopidogrel (Plavix), drugs that treat pain associated with ulcers, such as omeprazole, antiseizure drugs such as mephenytoin, the antimalarial proguanil, and the anxiolytic diazepam.

The International Union of Basic and Clinical Pharmacology (IUPHAR) is a voluntary, non-profit association representing the interests of scientists in pharmacology-related fields to facilitate Better Medicines through Global Education and Research around the world.

<span class="mw-page-title-main">Ranolazine</span> Drug used to treat angina

Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth.

<span class="mw-page-title-main">Russ Altman</span> American biomedical scientist and academic

Russ Biagio Altman is an American professor of bioengineering, genetics, medicine, and biomedical data science and past chairman of the bioengineering department at Stanford University.

David Ofori-Adjei is a Ghanaian physician, medical researcher, academic and medical journal editor. His main areas of research are clinical pharmacology, pharmacogenetics, infectious diseases such as malaria, schistosomiasis, Buruli ulcer, and HIV/AIDS and public sector pharmaceutical management. He is currently the Editor-in-Chief of the Ghana Medical Journal.

Raymond L. Woosley is an American pharmacologist who is the founding president and chairman of the board for AZCERT, a not-for-profit organization dedicated to improved outcomes from the use of medications. Prior to leading AZCERT, he was founder and President of Critical Path Institute (C-Path). C-Path is an independent, non-profit organization created by the U.S. Food and Drug Administration (FDA) and the University of Arizona to help launch the critical path initiative. Previously, he has served as Vice-President for Health Sciences and Dean of the College of Medicine at the University of Arizona. He is Professor of Medicine and Biomedical Informatics in the University of Arizona College of Medicine - Phoenix, Arizona.

<span class="mw-page-title-main">UCL Institute of Ophthalmology</span>

The UCL Institute of Ophthalmology is an institute within the Faculty of Brain Sciences of University College London (UCL) and is based in London, United Kingdom. The institute conducts research and post-graduate teaching in the area of ophthalmology.

<span class="mw-page-title-main">Urs A. Meyer</span>

Urs Albert Meyer is a Swiss physician-scientist and clinical pharmacologist.

Professor Sir Munir Pirmohamed is a British clinical pharmacologist and geneticist. Since 2007 he has been the NHS Chair of Pharmacogenetics at the University of Liverpool.

Sussan Nourshargh is a British immunologist, pharmacologist, and professor of microvascular pharmacology and immunopharmacology. She founded the Centre for Microvascular research at Queen Mary University.

Iruka Okeke is a Nigerian pharmaceutical microbiologist currently holding the position of professor at the College of Medicine,University of Ibadan in Nigeria. Iruka's career is the study neglected enteric bacteria such as E. coli, known for their potential to cause fatal bloodstream and diarrheal infections. She advocates for the utilization of Genomics approaches to enhance surveillance and gain a better understanding of pathogen virulence. Iruka's research interests extend to combating antimicrobial resistance and investigating bacterial pathogenesis, epidemiology, and antimicrobial resistance of enteric bacteria. Iruka's contributions to the field have earned her recognition as a fellow of esteemed institutions such as the Nigerian Academy of Sciences, and African Academy of Sciences.[1]

<span class="mw-page-title-main">Ruth March</span> British genomic scientist

Ruth Eleanor March is a British genomic scientist who is senior vice president of precision medicine at AstraZeneca. She specialises in precision medicine and oncology. During the COVID-19 pandemic, March developed a diagnostic test for COVID-19.

<span class="mw-page-title-main">Matthias Schwab (pharmacologist)</span> German pharmacologist

Matthias Schwab is a German doctor and university lecturer. He is director of the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology located on the campus of the Robert-Bosch-Hospital in Stuttgart, an institution of the Robert Bosch Stiftung, and holder of the Chair of Clinical Pharmacology at the University of Tübingen as well as Medical Director of the Department of Clinical Pharmacology at the University Hospital Tübingen.

<span class="mw-page-title-main">Linaprazan</span> Pharmaceutical molecule

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB). Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.

<span class="mw-page-title-main">AION Labs</span>

AION Labs is an Israeli venture studio focused on the adoption of artificial intelligence (AI) and machine learning (ML) in pharmaceutical discovery and development processes.

References

  1. ↑ "ISP Stories - Uppsala University". www.uu.se. 13 May 2024. Retrieved 7 August 2024.
  2. ↑ International, HUGO. "HUGO African Prize". HUGO International. Retrieved 7 August 2024.
  3. ↑ "Collen Masimirembwa". gcgh.grandchallenges.org. Retrieved 7 August 2024.
  4. ↑ "My Bibliography - NCBI". www.ncbi.nlm.nih.gov. Retrieved 7 August 2024.
  5. 1 2 3 "Collen Masimirembwa". urban-press. Retrieved 30 December 2023.
  6. 1 2 3 4 "Dr. Collen Masimirembwa, President and Founder of The African Institute of Biomedical Science and Technology, Harare, Zimbabwe" (PDF). Retrieved 30 December 2023.
  7. 1 2 3 4 "Collen MASIMIREMBWA". ICGEB. 16 April 2023. Retrieved 30 December 2023.
  8. ↑ "International Science Programme (ISP)". Uppsala University, Sweden. 14 September 2023. Retrieved 30 December 2023.
  9. ↑ Olagunju, Abdulrahman (12 October 2023). "Increasing breast cancer drug dose would improve outcomes for black patients".
  10. ↑ "Professor Collen Masimirembwa". EDCTP. 24 July 2020. Retrieved 30 December 2023.
  11. 1 2 "Collen Masimirembwa". Global Grand Challenges. 15 October 2021. Retrieved 30 December 2023.
  12. ↑ International, HUGO. "HUGO African Prize". HUGO International. Retrieved 6 August 2024.
  13. ↑ https://www.edctp.org/web/app/uploads/2020/10/EDCTP-case-studies-2020-TMA-Fellowships.pdf
  14. ↑ "Collen Masimirembwa". gcgh.grandchallenges.org. Retrieved 6 August 2024.
  15. ↑ "Awards - PMWC Silicon Valley". PMWC Precision Medicine World Conference. Retrieved 6 August 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.